We are live on
!
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$522M
1-Year Est. Return
281.95%
This Fund
S&P 500
This Quarter
Est. Return
-9.68%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
-$38.1M
(-10%)
Cap. Flow
+$16M
Cap. Flow
% of AUM
4.71%
Top 10 Holdings %
Top 10 Hldgs %
55.38%
Holding
79
New
17
Increased
14
Reduced
10
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunocore
IMCR
|
+$17.3M |
| 2 |
Immunovant
IMVT
|
+$10.9M |
| 3 |
Merck
MRK
|
+$10.5M |
| 4 |
GSK
GSK
|
+$10.3M |
| 5 |
ACLX
Arcellx
ACLX
|
+$7.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$11.7M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$11.2M |
| 3 |
Roivant Sciences
ROIV
|
+$9.22M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$8.08M |
| 5 |
Insmed
INSM
|
+$7.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.45% |
| 2 | Financials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| – | – |
-1,200,000
| Closed | -$876K |
|
77
Kyverna Therapeutics
KYTX
$452M
| – | – |
-41,000
| Closed | -$1.02M |
|
|
ACHL
78
DELISTED
Achilles Therapeutics
ACHL
| – | – |
-1,385,750
| Closed | -$1.73M |
|
|
EFTR
79
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| – | – |
-132,793
| Closed | -$1.91M |
|
Similar funds
JE
GS
LT
WFA
TCM
SCM
ETS
CM
Stempoint Capital's Q2 2024 Portfolio in Review
As of Q2 2024, Stempoint Capital held 79 positions worth $340M, down 10% from $378M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Stempoint Capital deployed $16M of net new capital in Q2 2024, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Immunocore: 339,351 shares worth $11.5M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $11.2M trimmed.
- Stempoint Capital's largest Q2 2024 buy was Immunocore: 339,351 shares worth $11.5M.
- Stempoint Capital added most to Immunovant in Q2 2024, an estimated $10.9M increase.
- Stempoint Capital's biggest Q2 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $11.2M.
- Stempoint Capital fully exited Eli Lilly in Q2 2024, selling an estimated $11.7M.
- Stempoint Capital's ten largest holdings make up 55% of its $340M portfolio in Q2 2024.
- Stempoint Capital opened 17 new positions and closed 36 in Q2 2024.
- Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $340M.
Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.